Test ID IETG Interference Evaluation Heterophile, Thyroglobulin Tumor Marker, Serum
Ordering Guidance
If interference or heterophile testing is not required, order HTG2 / Thyroglobulin, Tumor Marker, Serum.
For fine-needle aspirate specimens, order TFNAB / Thyroglobulin, Tumor Marker, Fine-Needle Aspiration Biopsy Needle Wash.
Specimen Required
Patient Preparation: For 12 hours before specimen collection do not take multivitamins or dietary supplements containing biotin (vitamin B7), which is commonly found in hair, skin, and nail supplements and multivitamins.
Collection Container/Tube: Red top (serum gel/SST are not acceptable)
Submission Container/Tube: Plastic vial
Specimen Volume: 2.5 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Useful For
Evaluation of suspected interference from heterophile antibodies causing a falsely elevated thyroglobulin result
Highlights
The specimen will be evaluated for potential heterophile antibody interference in the Beckman Access Thyroglobulin (Tg) Immunoassay.
In the absence of anti-thyroglobulin antibodies, the presence of heterophile interference is not suspected when the Tg concentration in the alternate platform evaluation, dilutions, and heterophile blocking tube pretreatment are substantially altered.
Profile Information
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
TGII | TG, Interference Interpretation | No | Yes |
TGQN | Thyroglobulin, Tumor Marker, S | Yes, (Order HTG2) | Yes |
TGABI | Thyroglobulin Antibody, S | Yes, (Order HTG2) | Yes |
TGMS | Thyroglobulin, Mass Spec., S | Yes | Yes |
Testing Algorithm
Heterophile antibody evaluation consists of comparison of thyroglobulin (Tg) concentrations obtained by immunoassay with the following:
-Tg concentrations following pretreatment with commercial heterophile blocking reagents
-Tg concentrations obtained by mass spectrometry
-Tg concentrations obtained by serial dilutions of the sample
In all samples the presence of anti-thyroglobulin antibodies are evaluated.
Method Name
TGQN/TGABI: Immunoenzymatic Assay
TGMS: Tryptic Protein Fragmentation, purified with Immunocapture, Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
(This service is performed pursuant to an agreement with SISCAPA Assay Technologies Inc. covering US Patent 7,632,686)
TGII: Medical Interpretation
Reporting Name
Interference Eval, Heterophile, TGSpecimen Type
Serum RedSpecimen Minimum Volume
2 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum Red | Refrigerated (preferred) | 7 days | |
Frozen | 30 days | ||
Ambient | 72 hours |
Reference Values
THYROGLOBULIN TUMOR MARKER
Athyrotic: <0.1 ng/Ml
Intact thyroid: ≤33 ng/mL
THYROGLOBULIN, MASS SPECTROMETRY
Athyrotic: <0.2 ng/mL
Healthy individuals with intact, functioning thyroid: ≤33 ng/mL
THYROGLOBULIN ANTIBODY
<1.8 IU/mL
Reference values apply to all ages.
Day(s) Performed
Monday through Saturday
Report Available
3 to 6 daysPerforming Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
84432
86800
84432
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
IETG | Interference Eval, Heterophile, TG | 101626-0 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
62749 | Thyroglobulin, Mass Spec., S | 3013-0 |
35998 | Interpretation | 59462-2 |
TGABI | Thyroglobulin Antibody, S | 56536-6 |
TGQN | Thyroglobulin, Tumor Marker, S | 96460-1 |
TGIF | TG, Interference Heterophile | 101627-8 |
TGIN | TG, Interpretation | 101628-6 |